Target intelligence / Profile preview

CRISPR-associated endonuclease Cas9 (Cas9)

Target
Cas9
Molecular classification
Enzyme, Endonuclease, RNA-guided endonuclease, DNA-binding protein
01

Overview

CRISPR-associated endonuclease Cas9 (Cas9) is an RNA-guided DNA endonuclease derived from the Type II CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) adaptive immune system of bacteria, most notably Streptococcus pyogenes. In its native bacterial context, Cas9 functions to defend against invading bacteriophages and plasmids by unwinding foreign DNA and introducing site-specific double-strand breaks (DSBs) guided by a dual-RNA complex (crRNA and tracrRNA). In biotechnology and medicine, this system has been engineered into a single-guide RNA (sgRNA) and Cas9 complex, enabling highly precise, programmable genome editing in eukaryotic cells. Upon binding to a target genomic locus adjacent to a protospacer adjacent motif (PAM), Cas9 utilizes its RuvC and HNH nuclease domains to cleave both strands of DNA. The resulting DSBs are repaired by the host cell's endogenous DNA repair pathways, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), allowing for gene knockout, gene correction, or gene insertion. Cas9-based therapeutics, such as the FDA-approved exagamglogene autotemcel (Casgevy), are being actively developed to treat a wide range of human diseases, including genetic disorders (e.g., sickle cell disease, beta-thalassemia, transthyretin amyloidosis), cancers, and chronic viral infections. However, therapeutic translation faces challenges such as off-target editing, potential genotoxicity, and host immunogenicity against the bacterial Cas9 protein.

Other names
CRISPR-associated protein 9Csn1SpCas9SaCas9RNA-guided DNA endonuclease Cas9
02

Mechanism of action

RNA-guided double-stranded DNA cleavage to facilitate gene knockout, correction, or insertion via cellular repair pathways.

03

Biological functions

DNA cleavageGenome editingBacterial adaptive immunityGene expression regulation
04

Disease associations

Genetic disorderCancerInfectionCardiovascular diseaseSickle cell diseaseBeta-thalassemiaTransthyretin amyloidosisHereditary angioedema
05

Safety considerations

Off-target editingChromosomal translocationsImmunogenicity (anti-Cas9 antibodies)Genotoxicityp53-mediated DNA damage responseOn-target large deletions or rearrangements
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Indel frequencyTarget gene editing efficiencyFetal hemoglobin (HbF) levelsSerum transthyretin levelsOff-target cleavage events

Beyond the preview

Go deeper on CRISPR-associated endonuclease Cas9 (Cas9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRISPR-associated endonuclease Cas9 (Cas9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call